Preclinical <i>In Vitro</i>, <i>In Vivo</i>, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers
Abu Syed Md Anisuzzaman(Emory University), A.R.M. Ruhul Amin(Emory University), Fadlo R. Khuri(American University of Beirut Medical Center), James R. Fuchs(The Ohio State University), Zhuo Chen(Fujian Institute of Research on the Structure of Matter), Yuan Liu(Center for Life Sciences), Dongsheng Wang(Emory University), Mohammad Aminur Rahman(Nagoya University), Dong M. Shin(Emory University), Abedul Haque(The University of Texas MD Anderson Cancer Center), Selwyn J. Hurwitz(Emory University), Gabriel Sica(Emory University)
Cited by 11
Related Papers
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
|Proceedings of the National Academy of Sciences|2017|899
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
|The Lancet Oncology|2013|748
B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity
|Immunity|2003|702